<DOC>
	<DOCNO>NCT01916174</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial ass expect biological equivalence two formulation insulin degludec/liraglutide ( IDegLira ) identical active ingredient healthy volunteer .</brief_summary>
	<brief_title>A Trial Demonstrate Bioequivalence Between Two Insulin Degludec/Liraglutide Formulations , B5 V2 Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Healthy male female volunteer Body mass index ( BMI ) 18.5 27.0 kg/m^2 ( inclusive ) Body weight 60 90 kg ( inclusive ) Female childbearing potential pregnant , breastfeed intend become pregnant use adequate contraceptive method . Adequate contraceptive measure implant , injectables , combine oral contraceptive , hormonal intrauterine device , sexual abstinence vasectomise partner History presence cancer , clinically significant cardiovascular , respiratory , metabolic , renal , hepatic , gastrointestinal , endocrine ( incl . diabetes ) , haematological , dermatological , venereal , neurological , psychiatric disease major disorder Use prescription nonprescription medication , except paracetamol , acetylsalicylic acid , contraceptive vitamin ( include megadose vitamin therapy , judge investigator ) within 2 week trial Drug alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>